Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,297 papers from all fields of science
Search
Sign In
Create Free Account
Coxsackievirus A8 Ab:ACnc:Pt:Ser:Qn
Known as:
Coxsackievirus A8 Ac [Arbitraire/Volume] Sérum ; Numérique
, Coxsackievirus A8 Ac:Concentration arbitraire:Temps ponctuel:Sérum:Quantitatif
, Coxsackievirus A8 Antibody:Arbitrary Concentration:Point in time:Serum:Quantitative
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
5 relations
ACnc
Antibodies
Coxsackie Viruses
Microbiology procedure
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
How Amphipols Embed Membrane Proteins: Global Solvent Accessibility and Interaction with a Flexible Protein Terminus
M. Etzkorn
,
M. Zoonens
,
L. Catoire
,
J. Popot
,
S. Hiller
Journal of Membrane Biology
2014
Corpus ID: 33330448
AbstractAmphipathic polymers called amphipols provide a valuable alternative to detergents for keeping integral membrane proteins…
Expand
2009
2009
Association between the bovine major histocompatibility complex and chronic posterior spinal paresis--a form of ankylosing spondylitis--in Holstein bulls.
C. A. Park
,
H. Hines
,
D. Monke
,
W. T. Threlfall
Animal Genetics
2009
Corpus ID: 9749538
A highly significant association was found between the bovine MHC class I antigen BoLA-A8 and a form of vertebral osteophytosis…
Expand
2008
2008
Increased frequency of HL-A8 in Sjogren's syndrome.
M. Gershwin
,
I. Terasaki
,
R. Graw
,
T. Chused
Tissue Antigens
2008
Corpus ID: 44684718
The histocompatibility antigen, HL-A8, was found to be elevated in patients with Sjogren's syndrome. Among 24 patients, the…
Expand
2008
2008
HL-A8 and LD-8a in patients with myasthenia gravis.
E. Möller
,
L. Hammarström
,
E. Smith
,
G. Matell
Tissue Antigens
2008
Corpus ID: 31672529
The frequency of HL-A8 in myasthenia gravis is markedly increased in women (60-80%) but not in men. The MLC determinant, LD-8a…
Expand
Highly Cited
2005
Highly Cited
2005
Antivascular Therapy for Orthotopic Human Ovarian Carcinoma through Blockade of the Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptors
P. Thaker
,
S. Yazıcı
,
+6 authors
A. Sood
Clinical Cancer Research
2005
Corpus ID: 10914228
Purpose: We determined whether the administration of the tyrosine kinase inhibitor, AEE788, which targets the epidermal growth…
Expand
1997
1997
Analog Binding Properties of Insulin Receptor Mutants
D. Mynarcik
,
P. F. Williams
,
Lauge Schaffer
,
G. Q. Yu
,
J. Whittaker
Journal of Biological Chemistry
1997
Corpus ID: 37734637
Recent studies utilizing alanine scanning mutagenesis have identified a major ligand binding domain of the secreted recombinant…
Expand
1977
1977
Histocompatibility antigens in chronic liver disease.
Scott Bb
,
S. Rajah
,
M. Losowsky
Gastroenterology
1977
Corpus ID: 37225889
Highly Cited
1976
Highly Cited
1976
Histocompatibility antigens in systemic lupus erythematosus.
Marc A. Goldberg
,
F. Arnett
,
F. Arnett
,
W. Bias
,
L. Shulman
Arthritis & Rheumatism
1976
Corpus ID: 42459853
Histocompatibility (HL-A) antigens were determined in 120 patients with systemic lupus erythematosus (SLE) and 120 matched…
Expand
1976
1976
Blood Coagulation and Fibrinolysis in Thyroid Disease
N. Farid
,
B. Griffiths
,
J. Collins
,
W. Marshall
,
D. W. Ingram
Thrombosis and Haemostasis
1976
Corpus ID: 21302435
Summary Fibrinolytic activity and factor VIII concentration were studied in 30 patients with moderate to minimal hypothyroidism…
Expand
Review
1974
Review
1974
Associations between HL-A histocompatibility antigens and non-malignant diseases
L. Ryder
,
L. Nielsen
,
A. Svejgaard
Humangenetik
1974
Corpus ID: 25688284
SummaryData on associations between antigens of the major human histocompatibility system, HL-A, and various non-malignant…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE